Verapamil (VER) Enhances the Cytotoxic Effects of Docetaxel and Vinblastine Combined Therapy Against Non-Small Cell Lung Cancer Cell Lines

Abstract

Lung cancer is one of the foremost tumor-associated cause of death in the world. Most of the patients with NSCLC possesses an advanced disease at diagnosis, and are thus probable subject for systemic therapy. This study aims to evaluate the cytotoxicity of vinblastine and docetaxel combined therapy for the treatment of NSCLC, as well as verapamil (VER) enhancement of the combined therapy. We conducted P-glycoprotein (P-gp) gene expression, protein expression with RT-PCR and western blot respectively, apoptotic response of the combined therapy with VER is also determined using DAPI staining (%). Result of DAPI staining confirmed combination therapy promotes cell apoptosis to greater extent as compared to each drug alone. Real-time RT-PCR analysis revealed that mdr-1 expression level increased 6 fold with docetaxel (40 nM) and 2 fold with vinblastine (30 nM) after 24 h (p<0.001). Consequently, combination therapy reduced drug-induced up-regulation of mdr-1 significantly (p<0.05). VER with the drug combination increased P-gp expression (p<0.05). These data provide evidence showing combined therapy is a better approach to improve the efficacy of chemotherapy and decreasing drug resistance.

Key words

verapamil - docetaxel - vinblastine - lung cancer

• References

• 1 Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012, CA. Cancer J Clin 2012; 62: 10-29 doi:10.3322/caac.20138.Available
• 2 Molina JR, Yang P, Cassivi SD. et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008; 83: 584-594 doi:10.4065/83.5.584
• 3 Navada S, Lai P, Schwartz A. et al. Temporal trends in small cell lung cancer: Analysis of the national surveillance, epidemiology, and end–results (SEER) database. J Clin Oncol. 2006; 24: 7082 http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/7082
• 4 Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin. Proc. 2008; 83: 355-367 doi:10.4065/83.3.355
• 5 Ardizzoni A, Boni L, Tiseo M. et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J. Natl. Cancer Inst. 2007; 99: 847-857 www.ncbi.nlm.nih.gov/pubmed/17551145
• 6 Sedlacek SM. First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine. Oncology. 1993; 50 (Suppl. 01) 16-21 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8483557
• 7 Briest S, Stearns V. Chemotherapeutic Strategies for advanced breast cancer. Oncol. (Willist. Park 2007; 21: 1325-1335 1340 http://www.ncbi.nlm.nih.gov/pubmed/18080617
• 8 Gregory RK, Smith IE, Norton A. et al. vinblastine and carboplatin: Effective outpatient chemotherapy for advanced non-small cell carcinoma of thelung (NSCLC). Clin. Oncol. 2001; 13: 483-487 http://www.scopus.com/inward/record.url?eid=2-s2.0-0035685736&partnerID=40&md5=d05a0c968457f1c0e7ac82bf20980fbc
• 9 Aaronson NK, Ahmedzai S, Bergman B. et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 1993; 85: 365-376 doi:10.1093/jnci/85.5.365
• 10 Nabholtz JM, North S, Smylie M. et al. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol. 2000; 27: 11-18 http://www.ncbi.nlm.nih.gov/pubmed/10810933
• 11 de Wit R, Kruit WH, Stoter G. et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br. J. Cancer. 1998; 78: 1342-1345 http://www.ncbi.nlm.nih.gov/pubmed/9823976%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2063192
• 12 Samadi N, Gaetano C, Goping IS. et al. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis. Oncogene 2009; 28: 1028-1039 doi:10.1038/onc.2008.442\ronc2008442 [pii]
• 13 Kim YJ, Lee CJ, Lee U. et al. Tamoxifen-induced cell death and expression of neurotrophic factors in cultured C6 glioma cells. J. Neurooncol. 2005; 71: 121-125 doi:10.1007/s11060-004-0984-z
• 14 Airoldi M, Cattel L, Pedani F. et al. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer. Acta Oncol. (Madr) 2003; 42: 186-194 doi:10.1080/02841860310010709
• 15 Airoldi M, Cortesina G, Giordano C. et al. Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med. Oncol. 2003; 20: 19-24 doi:10.1385/MO:20:1:19
• 16 Campone M, Blasinska-Morawiec M, Tekiela A. et al. Phase II study of vinorelbine (alternating intravenous and oral) in combination with docetaxel as first-line chemotherapy in metastatic breast cancer. Cancer Chemother. Pharmacol. 2009; 63: 937-943
• 17 Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin. Oncol. 1999; 26: 3-7 http://www.ncbi.nlm.nih.gov/pubmed/10604261
• 18 McGrogan BT, Gilmartin B, Carney DN. et al. Taxanes, microtubules and chemoresistant breast cancer. Biochim. Biophys. Acta - Rev. Cancer 2008; 1785: 96-132 doi:10.1016/j.bbcan.2007.10.004
• 19 Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE. et al. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468-7485 doi:10.1038/sj.onc.1206948